Lin Huang Email and Phone Number

嘉士腾医药是一家创新驱动的企业，致力于成为中国领先的精准医疗方案提供商。公司打造行业领先的类器官技术平台，为肿瘤患者提供最及时、最精准的用药方案；帮助肿瘤创新药研发企业设计最有效的新药开发路径与临床试验方案。嘉士腾医药兼具优质药品的配套供应能力，全方位满足客户需求。公司以靶向药和高临床价值用药为核心，开发、引进精准医疗配套药物。公司按照上市许可人持有人制度(MAH）通过自主开发、联合开发、以及授权引进美国FDA/欧盟认证的高端制剂产品来构建优质产品结构。嘉士腾医药成立于重庆两江新区，通过基金投资的方式设立，国内知名医药上市公司大股东参与基金投资。公司核心管理团队均长期任职于国内外大型知名医药上市企业，具备丰富的医药企业运营管理经验。Kingbiotech Co. is an innovation-driven enterprise, committed to becoming a leading precision medicine provider. The company has built an advanced Organoid technology platform to provide the most timely and precision medication plan for cancer patients, also support innovative drug research and development companies design the most effective new drug development model and clinical trial program. Kingbiotech and its associated entities also have the capability to develop and supply precision medicine supporting drugs, with targeted drugs and high clinical value drugs as the core, to meet customer needs in comprehensive way.

Elion Healthcare is one of the four core businesses of Elion Group. Founded in 1988, Elion Group is a leader in ecological restoration and a global desertification control leader recognized by the United Nations. Elion Group owns a public listed company "Elion Clean Energy Corp." (Shanghai Stock Exchange, since 2000), by the end of 2017, the assets of Elion Group had exceeded 100 billion CNY, and had more than 8000 employees. According to the evaluation and identification of the UN Environment Agency, Elion Group has created more than 500 billion CNY of ecological wealth in 30 years. The group was awarded the "China Poverty Alleviation Award" and the "Land Greening Award" by the Chinese government, the "Global Leader in Sand Control" award and the "Earth Defender Lifetime Achievement Award" by the United Nations. Elion Group takes "clear waters and green mountains are gold and silver mountains" as its eternal value pursuit. It has been committed to ecological civilization construction from desert to city for a long time. Its main business covers ecological restoration, cleanliness and environmental protection, healthcare and financial business.

Responsible for the general operation and management of the company, lead the company management team to achieve substantial improvement in business performance, promote the strategic expansion and development of the company, and implement asset merger and acquisition projects. Hainan Shuangcheng Pharmaceutical Co., Ltd. is a high-tech enterprise founded in 2000, featuring polypeptides, specializing in drug research and development, production and sales. The company was listed on the Shenzhen Stock Exchange on August 2012 (stock code 002693). It has rich experience in drug research and development, registration, production and marketing of polypeptide drugs. It has successfully developed several famous polypeptide drugs such as Thymalfasin, Somatostatin and Thymopentin for injection. The company has the US FDA approved lyophilized injection and polypeptide API facilities, which is also approved by EMA. The company has built an international standard production base in Haikou city and Ningbo Hangzhou Bay Development Zone.

Fully responsible for the management of the company. Develop new investment project opportunities and supervise the operation of subsidiaries. For the subsidiaries qualified for IPO, make corporation structuring, listing planning and guidance. Post-investment management of the subsidiaries, including strategic management, business support, industry and policy research, collaborative integration, and culture construction.

In charge of general operation of the company, design and lead the management team to execute the strategy, manage the market capitalization of the company.PKU HEALTHCARE CORP. is former "Southwest Synthetic Pharmaceutical Corp., Ltd.", listed in Shenzhen Stock Exchange, stock code 000788). It is one of the leading and growing pharmaceutical companies in China, with USD 450million revenue, engaged in manufacturing, marketing and sales, distributing API and finished dosage forms, including 4 manufacturing plants, 5 pharmaceutical sales and distribution subsidiaries.

Directly in charge of international business (marketing and sales, global business development, new product selection and Project decision, import supply chain management), regulatory affairs, procurement; and coordinate overall operation in the company.

In charge of international business, regulatory affairs. In the past six years, led the team to increase the number of US FDA and EU approved products from 4 to 15.